The AML/CFT program must be in writing and made available upon request. Unlike the current rules, which focus on board approval, the proposal would allow approval by the board, an equivalent governing ...
On April 7, 2026, the U.S. Department of Treasury’s Financial Crimes Enforcement Network (FinCEN) issued a notice of proposed rulemaking ...
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
The last time I spoke about Syndax Pharmaceuticals (SNDX), it was with respect to a Seeking Alpha article entitled "Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity." With respect ...
Revuforj, a menin inhibitor, is under priority review for relapsed or refractory mutant NPM1 AML, with a target action date of October 25, 2025. The AUGMENT-101 trial demonstrated Revuforj's efficacy, ...
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results